Pharmcology Flashcards
NANC innervation nonadenergic/ noncholinergic
Bronchodilation
Transmitters: VIP and NO
In asthma substance P may cause bronchoconstriction
Parasympathetic innervation
Ach from vagus nerve stimulates M3 receptors
Bronchoconstriction
No sympathetic innervation but
B2 receptors on airway smooth muscle
Circulating adrenaline released from adrenal medulla causes bronchodilation
B2 receptors on mast cells (normally release bronchoconstrictors eg histamine) - inhibits activity
B2 stimulation promotes muco-ciliary escalator activity
Mechanical receptors
Rapidly adapting receptors RAR also known as irritant or cough receptors cause bronchoconstriction
Stimulation by foreign bodies or irritants initiates reflex with afferent and efferent arms in vagus result in contraction smooth muscle
Slowly adapting pulmonary stretch receptors PSR cause bronchodilation, stretch fibres in afferent vagus nerve
Mast cells
Present in airway walls
Mediators released on degranulation causing bronchoconstrction
Eg histamine, platelet activating factors , leukotrienes
Contribute to asthma pathology
CO2
Bronchodilation
Builds up in areas of lung that are under ventilated
Important for ventilation- perfusion matching
Radial traction
Airways embedded in lung parenchyma
Parenchyma splints airways open
Inflation increases radial traction and reduces airway resistance
During inspiration lung expands stretching parenchyma fibres increasing radial traction pulling out airways increasing diameter reducing airway resistance
Alveolar interdependence
Neighbouring alveoli share walls
Mechanical tethering keeps conducting airways open
Loss of radial traction and alveolar interdependence increases airway resistance in COPD
Asthma
Episodes of bronchoconstriction
Bronchial hypersensitivity- airway mucosa inflammation: infiltration of immune cells and thickening
Increased airway secretions
Pharmacological treatment can target bronchoconstrictor or inflammatory components
Anti-cholinergics/muscarinic antagonists
Block bronchoconstricting action of ACh
Ipratropium: inhaled quaternary nitrogen in structure prevents systemic absorption and reduces side effects (dry mouth and cough)
Tachycardia, relax bladder, inhibit intestine activities, inhibit salvia etc
Used in COPD with salbutamol
B2 agonists
Noradrenaline or adrenaline
Stimulates the AC/cAMP/PKA pathway to cause bronchodilation and reduce inflammation (mast cells inhibited)
Salbutamol: short acting inhaled, side effects: tachycardia, tremor, airway hyper responsiveness can develop tolerance
Salmeterol/turbutaline: long acting/ slow onset, used in pregnancy’s not appropriate in asthma attack
Methylxanthines
PDE(phosphodiesterase) inhibitors: increased cAMP and cause bronchodilation and reduce inflammation
Administered orally
Theophylline/aminophylline: oral, narrow therapeutic window side effects: headache, restlessness, abdominal symptoms, arrhythmias
Reported drug interactions use declined
Aspirin induced asthma
Sensitivity develops in adulthood women>men
Symptoms: rhinorrhea, nasal congestion, sinusitis
5-lipoxygenase unregulated increasing production leukotrienes
Montelukast used as a treatment- leukotriene receptor antagonist
Monoclonal anti-IgE antibodies
Omalizumab : s.c injection every 2-4 weeks, reduces circulating IgE and therefore reduces mast cell degranulation and inflammation, used in severe allergic asthma, in rare instances can cause anaphylaxis
Reduces bronchoconstriction
Histamine receptor antagonists
Ketotifen: oral H1 receptor antagonist, anti inflammatory after 6-12 weeks
Reduced reliance on steroids and bronchodilators
Few side effects: drowsiness